z-logo
open-access-imgOpen Access
Management of a Parkinson’s disease patient with severe COVID-19 pneumonia
Author(s) -
Jingwen Li,
Xi Long,
Chunli Zhu,
Ruiying Wang,
Shaoping Hu,
Tao Wang,
Jinghong Li,
Zhicheng Lin,
Nian Xiong
Publication year - 2020
Publication title -
therapeutic advances in chronic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.027
H-Index - 35
eISSN - 2040-6231
pISSN - 2040-6223
DOI - 10.1177/2040622320949423
Subject(s) - medicine , pneumonia , disease , coronavirus , covid-19 , parkinson's disease , intensive care medicine , encephalopathy , urinary system , pediatrics , infectious disease (medical specialty)
Elderly populations with underlying chronic diseases are more vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and have higher mortality. Parkinson’s disease (PD) is a neurodegenerative disease that occurs more often in elderly people. Currently, little is known about whether patients with PD are more susceptible to novel coronavirus disease 2019 (COVID-19) and whether the treatment of PD would affect the management of COVID-19 or vice versa. Here, we report a case of a PD patient with severe COVID-19 pneumonia in Wuhan, China. After diagnosis of COVID-19, this PD patient had worsening of motor symptoms, complicated with acute hypoxemic respiratory failure, urinary tract infection, and acute encephalopathy. In addition to treatment for COVID-19 and urinary tract infection, we adjusted anti-PD medicine by stepwise increasing of dose, resulting in better control of her mobility symptoms and non-motor symptoms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom